Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma
The ODAC meeting concluded that ide-cel showed a favorable risk/benefit profile for patients with pretreated relapsed/refractory multiple myeloma.
ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC
The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.
Survival Benefit Observed With Targeted Therapies in NSCLC Cohort Study
A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.
Team Effort Is Needed to Expand CAR T-Cell Therapy Access for LBCL
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS
Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
Bivalent CAR T-Cell Therapy Shows Tumor Shrinkage in Recurrent Glioblastoma
Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels.
Nivolumab/Chemo Approval Adds Options for Urothelial Carcinoma, Expert Says
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Evaluating Secondary Primary Malignancy Risk After CAR T-cell Therapy
In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.
ASH 2023: The Most Relevant Multiple Myeloma Data Presented
Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.
Nivolumab/Chemo Yields Meaningful Survival in Advanced Gastric/GEJ Cancer
Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
CAR T-Cell Therapy Access Expansion for LBCL Sees “Early Success”
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Assessing Other Options Aside from Surgery Shows “Promise” in Breast Cancer
Targeted imaging and biopsy may accurately identify patients with breast cancer who do not have residual disease, according to Henry Kuerer, MD, PhD, FACS, CMQ.
Data Support Impact of Precision Medicine in Managing Prostate Cancer
Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.
Robotic-Assisted Mastectomy Has Potential, but Is a Cautionary Tale
The use of a robot to aid in nipple-sparing surgery has been a controversial topic, although ongoing trials may show its potential.
Brentuximab Vedotin Combo Significantly Improves Survival in R/R DLBCL
Treatment with brentuximab vedotin, lenalidomide, and rituximab yielded a progression-free survival benefit in the phase 3 ECHELON-3 trial.
Ide-cel Improves HRQOL Vs Standard Treatment in R/R Multiple Myeloma
Patient-reported outcomes support the clinical benefits of ide-cel among patients with relapsed/refractory multiple myeloma.
Geographic, Racial Disparities Exist in CAR T, Bispecific Access in DLBCL
Strategies must be framed for addressing racial and geographic disparities in access for CAR T-cell and bispecific antibody therapy, according to the study authors.
Simple Hysterectomy Noninferior Vs Radical Hysterectomy in Cervical Cancer
Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.
FDA Lifts Partial Clinical Hold on NX-2127 Trial in B-Cell Malignancies
Investigators plan to reinitiate enrollment of patients with non-Hodgkin lymphoma as part of the phase 1a/1b NX-2127-001 trial.
The Impact of CAR T-Cell Therapy on Hematological Malignancies
Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.
Addressing Rising Cancer Incidence and Burden in Younger Populations
Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.
HLA Mismatch URD Transplant Offers Alternative to GVHD Population
Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.
HER3-DXd May Lead to an Additional Treatment Option in EGFR+ NSCLC
Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.
SCLC is ‘On the Cusp’ of Being Better Understood, Says Expert
The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.
Detailing the Impact on SOC in GI Cancer After ASCO GI
Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.
Evidence Shows Racial Disparities in Radiation Oncology for Breast Cancer
Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.
FDA Committee Votes to Support Pegulicianine in Breast Cancer Surgery
Findings from the INSITE trial support the Medical Imaging Drugs Advisory Committee’s positive opinion on pegulicianine for breast cancer surgery.